PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

By P. Nghiem, S. Bhatia, E. Lipson, R. Kudchadkar, Natalie J. Miller, L. Annamalai, S. Berry, E. Chartash, A. Daud, S. Fling and 21 more. New England Journal of Medicine, 2016

1,115 citations recorded by the source corpus.

Subfields: Aerospace Engineering, Electrical and Electronic Engineering, Oncology

View Paper: https://www.semanticscholar.org/paper/2614490bfa9463185e8236081682e5aa82aa6fa2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018, background): “Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016, background): “Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney”
Molecular profiling for precision cancer therapies (2020, background): “The second cohort in microsatellite stable colorectal cancer with TMB between 11 and 22 mutations per megabase showed limited clinical benefit, leading to the closure of the arm [39, 167, 172].”
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers (2017, background): “Virus-associated Merkel cell carcinomas are known to carry a lowmutational burden (43–45); however, these tumors are responsive to PD-1/PD-L1 blockade (46).”
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “001) (Figure 2).(14-50) The predicted incidence of hypothyroidism ranged from 3.”
Comparison Between UMAP and t-SNE for Multiplex-Immunofluorescence Derived Single-Cell Data from Tissue Sections (2019, background): “Among the 119 biopsies included and with a median follow-up of 73 months (4-160), 5-year overall survival was 39.”
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018, background): “of patients 240 759 Median age, years (range) 66 (22-92) 66 (22-93) .”